NSCLC metastatic/no molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 31/05/2019)

1st line
IPSOS (Roche)
A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naïve advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.

LUNG037 M7824 versus PEMBROLIZUMAB (Merck)
A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer.

2th line 
Currently no trials

3th line 
Currently no trials
New trial in start-up: ORION: Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer